Nafarelin

Revision as of 03:41, 9 August 2011 by Lakshmi Gopalakrishnan (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

For patient information, click here.

Nafarelin
Clinical data
Pregnancy
category
  • X
Routes of
administration
Nasal spray
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Elimination half-life2.6 to 4 hours
Excretionrenal
Identifiers
CAS Number
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC66H83N17O13
Molar mass1321.6344 g/mol

WikiDoc Resources for Nafarelin

Articles

Most recent articles on Nafarelin

Most cited articles on Nafarelin

Review articles on Nafarelin

Articles on Nafarelin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Nafarelin

Images of Nafarelin

Photos of Nafarelin

Podcasts & MP3s on Nafarelin

Videos on Nafarelin

Evidence Based Medicine

Cochrane Collaboration on Nafarelin

Bandolier on Nafarelin

TRIP on Nafarelin

Clinical Trials

Ongoing Trials on Nafarelin at Clinical Trials.gov

Trial results on Nafarelin

Clinical Trials on Nafarelin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Nafarelin

NICE Guidance on Nafarelin

NHS PRODIGY Guidance

FDA on Nafarelin

CDC on Nafarelin

Books

Books on Nafarelin

News

Nafarelin in the news

Be alerted to news on Nafarelin

News trends on Nafarelin

Commentary

Blogs on Nafarelin

Definitions

Definitions of Nafarelin

Patient Resources / Community

Patient resources on Nafarelin

Discussion groups on Nafarelin

Patient Handouts on Nafarelin

Directions to Hospitals Treating Nafarelin

Risk calculators and risk factors for Nafarelin

Healthcare Provider Resources

Symptoms of Nafarelin

Causes & Risk Factors for Nafarelin

Diagnostic studies for Nafarelin

Treatment of Nafarelin

Continuing Medical Education (CME)

CME Programs on Nafarelin

International

Nafarelin en Espanol

Nafarelin en Francais

Business

Nafarelin in the Marketplace

Patents on Nafarelin

Experimental / Informatics

List of terms related to Nafarelin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Nafarelin is a gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Nafarelin may be used in the treatment of estrogen-dependent conditions (such as endometriosis or uterine fibroids), to treat central precocious puberty, and to control ovarian stimulation in IVF.

It is normally delivered via a nasal spray.

Nafarelin acetate is marketed by Searle under the brand name Synarel.

Side effects

Side effects of nafarelin are mostly related to the low estrogen state. Side effects include hot flashes, vaginal dryness, headaches, mood changes, and decreased interest in sex. Some patients may experience acne, muscle pain, reduced breast size, and irritation of the tissue inside the nose. These side effects should disappear after stopping the medication.

Template:SIB Template:Sex hormones Template:Pituitary and hypothalamic hormones and analogues


Template:WikiDoc Sources